Overview

A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program

Status:
Active, not recruiting
Trial end date:
2023-06-08
Target enrollment:
Participant gender:
Summary
This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program. The study will last about 2 years (29 visits).
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
LY3298176
Tirzepatide